Bavarian Nordic AS (OTCPK:BVNRY)
$ 9.8275 0.0375 (0.38%) Market Cap: 2.32 Bil Enterprise Value: 2.01 Bil PE Ratio: 21.99 PB Ratio: 1.52 GF Score: 76/100

Half Year 2024 Bavarian Nordic A/S Earnings Call Transcript

Aug 22, 2024 / 12:00PM GMT
Release Date Price: $13.51 (+3.92%)

Key Points

Positve
  • Bavarian Nordic A/S (BVNKF) reported exceptionally strong performance in Q2 and the first half of the year, driven by both travel health and public preparedness segments.
  • The Travel Health business saw a 15% year-on-year growth, particularly strong in the rabies segment.
  • The company is on track to complete the tech transfer of both rabies and TBE vaccines, enhancing future production capabilities.
  • The chikungunya vaccine program is advancing ahead of schedule, with submissions made to both EU and FDA regulatory authorities.
  • Bavarian Nordic A/S (BVNKF) has largely secured all anticipated contracts for the year, allowing them to confirm the upper range of their guidance for 2024.
Negative
  • The company faced a temporary stock out in Europe for the rabies vaccine, impacting market share.
  • Gross profit margin decreased to 44% in the first half of the year, down from previous levels, partly due to a water damage incident in their factory.
  • The current mpox outbreak in Africa presents challenges, including the need for emergency use authorization and regulatory approvals in multiple countries.
  • The company’s ability to ramp up production for mpox vaccines may require compromises in other production areas.
  • There is uncertainty regarding the timing and securing of additional orders related to the current mpox outbreak, impacting future guidance.
Rolf Sorensen;S;VP
Bavarian Nordic A;IR

/- -

Welcome, everyone, to this first half or Q2 update from Bavarian Nordic.

Q2 was full of news flow, and we are still in a very eventful period. And to do this presentation, we still have the A team, Paul Chaplin and Henrik Juuel, President and CEO, and Executive Vice President and CFO, to do the presentation and to do Q&A afterwards.

So before we start doing that, just go through the forward-looking statements. This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside our control, but could cause actual results to differ materially from the results discussed. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and other information that is not historical information.

We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

So

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot